What comes after the current obesity medicines?

What are researchers trying to improve?

Obesity is a long-term condition influenced by biology, environment, health and circumstances. Current medicines can help some people manage appetite and weight, but tolerability, practical access, nutrition and maintaining benefits remain important challenges. New treatments need to be assessed on these issues, not just changes on the scales.

Glucagon-like peptide-1 (GLP-1) is a hormone involved in appetite and blood sugar control. Semaglutide acts on its receptor, the structure through which it sends signals. Tirzepatide also acts on the receptor for glucose-dependent insulinotropic polypeptide (GIP). These are already established treatments, not evidence that every drug acting on related pathways will work similarly.

What is retatrutide, and can you use it now?

Retatrutide is an investigational medicine acting on GLP-1, GIP and glucagon receptors. Glucagon is a hormone involved in blood sugar and energy regulation. A drug acting at three receptors is sometimes called a triple agonist.

Retatrutide remains experimental and is not authorised for use in the UK. Trial findings cannot justify claims that it is safer, better tolerated or the right successor for an individual patient. Larger studies and continuing follow-up are needed to clarify benefits and harms.

Do not buy products advertised as retatrutide or as research peptides for self-injection. The UK regulator has warned that products sold outside legitimate clinical trials are supplied illegally and may not contain what their labels claim. Clinical-trial participation is different from buying an unapproved product online.

What other approaches are being studied?

Amylin-based treatments copy another hormone involved in fullness and stomach emptying. Researchers are studying these medicines alone and in combinations, including with semaglutide. Each combination needs its own evidence and regulatory assessment; do not combine appetite medicines yourself.

Other work explores additional gut-hormone pathways and longer-acting preparations. Changing the way a medicine is taken can introduce different risks or instructions, rather than automatically making it easier for everyone.

Are weight-management tablets still only a future possibility?

No. Oral Wegovy, containing semaglutide, received UK approval for adult weight management in June 2026. It is a daily prescription treatment with specific administration requirements. This does not mean every oral GLP-1 drug is authorised, nor that tablets and injections can be exchanged without a prescribing review.

Will technology or genetics replace ongoing care?

Digital support may help with self-monitoring and contact with a care team, but it does not replace clinical judgement. Genetic and gut-microbiome research is not proof that gene editing, commercial microbiome tests or supplements can provide a routine cure for common obesity.

Nutrition, suitable activity, psychological support and, for some people, metabolic surgery remain important options. There is no need to wait for an experimental medicine to discuss evidence-based care, and needing continued support is not a personal failure.